Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden
The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma...
Saved in:
Published in | European journal of cancer (1990) Vol. 123; pp. 83 - 91 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.12.2019
Elsevier Science Ltd |
Subjects | |
Online Access | Get full text |
ISSN | 0959-8049 1879-0852 1879-0852 |
DOI | 10.1016/j.ejca.2019.07.004 |
Cover
Abstract | The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.
A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.
By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm).
By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).
The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.
•The new American Joint Committee of Cancer (AJCC) classification for melanoma is controversially discussed, particular with regard to stage III.•This is crucial because the correct prognostication in stage III patients in extremely important for adjuvant treatment decision.•Sentinel node tumor load is a relevant prognostic parameter.•The diameter of the largest melanoma deposit enhances the prognostic value in stage III patients. |
---|---|
AbstractList | The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.
A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.
By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).
The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. •The new American Joint Committee of Cancer (AJCC) classification for melanoma is controversially discussed, particular with regard to stage III.•This is crucial because the correct prognostication in stage III patients in extremely important for adjuvant treatment decision.•Sentinel node tumor load is a relevant prognostic parameter.•The diameter of the largest melanoma deposit enhances the prognostic value in stage III patients. 1Background The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups. Patients and methods A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients. Results By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599). Conclusion The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.BACKGROUNDThe tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma classification. Therefore, we analysed the prognostic relevance of the SLN tumor burden in the stage III subgroups.A total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.PATIENTS AND METHODSA total of 736 patients with melanoma with positive SLN and long-term follow-up (mean, 64.4 months; median, 59.0 months) were assessed. SLN tumor burden was evaluated by the maximum diameter of the largest deposit in all patients.By univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).RESULTSBy univariate Kaplan-Meier analyses, melanoma-specific survival (MSS) of patients in stage IIIA, IIIB and IIIC and lower sentinel tumor burden (cut-offs ≤0.5 mm and ≤1 mm) was significantly better than that in patients with higher sentinel tumor load (>0.5 mm and >1 mm). By multivariate analysis using the Cox model, the maximum diameter of the largest deposit (cut-off ≤0.5 mm versus >0.5 mm and cut-off ≤1 mm as continuous variables) represented an independent prognostic parameter for MSS in stage III patients. Cut-off of 0.5 mm showed a slightly higher area under the receiver operating characteristic curve (AUC = 0.617) when than the cut-off of 1 mm (AUC = 0.599).The prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable.CONCLUSIONThe prognosis of patients with stage III melanoma can be determined more precisely if the SLN tumor burden is considered, also within the existing AJCC subgroups. Thus, this parameter should be included in future classifications, and our study provides benchmarks in estimating prognosis and counselling patients with melanoma with positive sentinel nodes beyond the 8th AJCC Cancer Staging Manual. The optimal cut-off remains for SLN tumor burden remains to be determined, but our results suggest that a cut-off lower than 1 mm is preferable. |
Author | Gutzmer, Ralf Leiter, Ulrike Gräger, Nikolai Keim, Ulrike Garbe, Claus Satzger, Imke |
Author_xml | – sequence: 1 givenname: Imke orcidid: 0000-0001-5983-2125 surname: Satzger fullname: Satzger, Imke email: satzger.imke@mh-hannover.de organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany – sequence: 2 givenname: Ulrike surname: Leiter fullname: Leiter, Ulrike organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany – sequence: 3 givenname: Nikolai surname: Gräger fullname: Gräger, Nikolai organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany – sequence: 4 givenname: Ulrike surname: Keim fullname: Keim, Ulrike organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany – sequence: 5 givenname: Claus surname: Garbe fullname: Garbe, Claus organization: Center for Dermatooncology, Department of Dermatology, Eberhard-Karls-University of Tübingen, Tübingen, Germany – sequence: 6 givenname: Ralf surname: Gutzmer fullname: Gutzmer, Ralf organization: Skin Cancer Center Hannover, Department of Dermatology and Allergy, Hannover Medical School, Carl Neuberg Strasse 1, D-30625 Hannover, Germany |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31677550$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkcGK1TAUhoOMOHdGX8CFBNy4aU3apkkHNzLoKIwIouuQpidMaprUpK3ctzeXO8PAXYyrwOH7Dif_f4HOfPCA0GtKSkpo-34sYdSqrAjtSsJLQppnaEcF7woiWHWGdqRjXSFI052ji5RGQggXDXmBzmvacs4Y2aHpGzjlw6SKNIO2xmqc1rjZTTlsPZ7VYsEvCf-1yx2eQ7KL3QCnPLMeHHb7ab7DPgyQrvAPcLAprwEH84gs6xQi7tc4gH-JnhvlEry6fy_Rr8-ffl5_KW6_33y9_nhb6KZmSzGYitKa910rCKXQk6bXqmVUg2GDGtoBdK97zmhlNG9rIwwVmjFhul63XVXXl-jdce8cw58V0iInmzS4_FUIa5JVTWnLhKh4Rt-eoGNYo8_XZaom-YSGs0y9uafWfoJBztFOKu7lQ5AZEEdAx5BSBCO1XXJ4wS9RWScpkYfO5CgPnclDZ5JwmTvLanWiPmx_UvpwlCDHuFmIMunclIbBRtCLHIJ9Wr860bWz3mrlfsP-f_I_-5_EsQ |
CitedBy_id | crossref_primary_10_1038_s41379_021_00835_5 crossref_primary_10_1186_s12885_022_09705_y crossref_primary_10_23736_S2784_8671_21_06958_3 crossref_primary_10_1007_s15004_020_8241_y crossref_primary_10_3390_cancers13102319 crossref_primary_10_1016_j_ejca_2020_04_022 crossref_primary_10_3390_cancers13122902 crossref_primary_10_1002_jso_27438 crossref_primary_10_1007_s00761_022_01108_9 crossref_primary_10_1186_s42047_020_00083_y crossref_primary_10_1080_0284186X_2021_1892820 crossref_primary_10_1080_0284186X_2023_2238558 crossref_primary_10_1016_j_ejca_2024_113912 crossref_primary_10_3389_fonc_2024_1416685 crossref_primary_10_1097_XCS_0000000000000088 |
Cites_doi | 10.1056/NEJMoa1708539 10.1002/1097-0142(20010601)91:11<2110::AID-CNCR1239>3.0.CO;2-Q 10.1016/j.ejca.2013.08.023 10.1002/cncr.25074 10.1016/j.ejca.2019.05.020 10.1200/JCO.2010.31.6760 10.1016/S1470-2045(16)00141-8 10.1200/JCO.2018.36.15_suppl.9500 10.1200/JCO.2011.37.1112 10.1097/CMR.0000000000000081 10.1016/j.ejca.2018.02.022 10.1002/cncr.24298 10.1200/JCO.2009.23.4799 10.3322/caac.21409 10.1200/JCO.2018.36.15_suppl.9591 10.1056/NEJMoa1709030 10.1016/j.ejca.2017.11.023 10.1056/NEJMoa1802357 |
ContentType | Journal Article |
Copyright | 2019 Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. Copyright Elsevier Science Ltd. Dec 2019 |
Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Science Ltd. Dec 2019 |
DBID | AAYXX CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
DOI | 10.1016/j.ejca.2019.07.004 |
DatabaseName | CrossRef PubMed Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | CrossRef PubMed AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium Oncogenes and Growth Factors Abstracts Toxicology Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | PubMed AIDS and Cancer Research Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-0852 |
EndPage | 91 |
ExternalDocumentID | 31677550 10_1016_j_ejca_2019_07_004 S0959804919304046 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29G 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 6PF 7-5 71M 8P~ 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABJNI ABLJU ABMAC ABMZM ABOCM ABUDA ABWVN ABXDB ACDAQ ACIEU ACIUM ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AGRDE AGUBO AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IHE J1W K-O KOM M29 M41 MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SPCBC SSH SSU SSZ T5K UV1 WUQ X7M XPP Z5R ZGI ZXP ~G- AACTN AAIAV ABLVK ABYKQ AFCTW AFKWA AHPSJ AJBFU AJOXV AMFUW DOVZS EFLBG LCYCR RIG ZA5 AAYXX AGRNS CITATION NPM 7TO 7U7 C1K H94 K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c435t-df21137b968011eb04bca651cef5dad6decbcb7512fc763f8f18c558f9bc69233 |
IEDL.DBID | AIKHN |
ISSN | 0959-8049 1879-0852 |
IngestDate | Fri Sep 05 09:18:48 EDT 2025 Sat Jul 26 02:28:11 EDT 2025 Wed Feb 19 02:31:07 EST 2025 Thu Apr 24 23:10:11 EDT 2025 Tue Jul 01 02:56:55 EDT 2025 Fri Feb 23 02:48:47 EST 2024 Tue Aug 26 19:28:13 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Tumor burden Prognosis Sentinel lymph node Melanoma |
Language | English |
License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c435t-df21137b968011eb04bca651cef5dad6decbcb7512fc763f8f18c558f9bc69233 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-5983-2125 |
PMID | 31677550 |
PQID | 2330968475 |
PQPubID | 2047469 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2311658827 proquest_journals_2330968475 pubmed_primary_31677550 crossref_citationtrail_10_1016_j_ejca_2019_07_004 crossref_primary_10_1016_j_ejca_2019_07_004 elsevier_sciencedirect_doi_10_1016_j_ejca_2019_07_004 elsevier_clinicalkey_doi_10_1016_j_ejca_2019_07_004 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | December 2019 2019-12-00 20191201 |
PublicationDateYYYYMMDD | 2019-12-01 |
PublicationDate_xml | – month: 12 year: 2019 text: December 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Oxford |
PublicationTitle | European journal of cancer (1990) |
PublicationTitleAlternate | Eur J Cancer |
PublicationYear | 2019 |
Publisher | Elsevier Ltd Elsevier Science Ltd |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Science Ltd |
References | Balch, Gershenwald, Soong (bib4) 2009 Dec 20; 27 Satzger, Meier, Zapf (bib13) 2014 Oct; 24 Gershenwald, Scolyer, Hess (bib5) 2017 Nov; 67 Van der Ploeg, van Akkooi, LU (bib9) 2014 Jan; 50 Verver, van Klaveren, van Akkooi (bib17) 2018 Jun; 96 Grob, Schadendorf, Lorigan (bib6) 2018 Mar; 91 van der Ploeg, van Akkooi, Rutkowski (bib8) 2011 Jun 1; 29 Satzger, Meier, Voelker (bib10) 2011; 29 Weber, Mandala, Del Vecchio (bib1) 2017 Nov 9; 377 Larkin, Hauschild, Santinami (bib18) 2018; 36 Eggermont, Blank, Mandala (bib19) 2019 Jul; 116 Madu, Franke, Van de Wiel (bib16) 2018; 36 Long, Hauschild, Santami (bib2) 2017 Nov 9; 377 Pflugfelder, Kochs, Blum (bib15) 2013 Jun; 11 Eggermont, Blank, Mandala (bib3) 2018; 378 Meier, Satzger, Völker (bib14) 2010 Jul 1; 116 Murali, Cochran, Cook (bib11) 2009. Nov 1; 115 Starz, Balda, Kramer (bib7) 2001; 91 Leiter, Stadler, Mauch (bib12) 2016 Jun; 17 Weber (10.1016/j.ejca.2019.07.004_bib1) 2017; 377 Eggermont (10.1016/j.ejca.2019.07.004_bib3) 2018; 378 Satzger (10.1016/j.ejca.2019.07.004_bib10) 2011; 29 Eggermont (10.1016/j.ejca.2019.07.004_bib19) 2019; 116 Verver (10.1016/j.ejca.2019.07.004_bib17) 2018; 96 Larkin (10.1016/j.ejca.2019.07.004_bib18) 2018; 36 Balch (10.1016/j.ejca.2019.07.004_bib4) 2009; 27 Grob (10.1016/j.ejca.2019.07.004_bib6) 2018; 91 Satzger (10.1016/j.ejca.2019.07.004_bib13) 2014; 24 Starz (10.1016/j.ejca.2019.07.004_bib7) 2001; 91 Murali (10.1016/j.ejca.2019.07.004_bib11) 2009; 115 Leiter (10.1016/j.ejca.2019.07.004_bib12) 2016; 17 Gershenwald (10.1016/j.ejca.2019.07.004_bib5) 2017; 67 Pflugfelder (10.1016/j.ejca.2019.07.004_bib15) 2013; 11 Van der Ploeg (10.1016/j.ejca.2019.07.004_bib9) 2014; 50 Meier (10.1016/j.ejca.2019.07.004_bib14) 2010; 116 van der Ploeg (10.1016/j.ejca.2019.07.004_bib8) 2011; 29 Madu (10.1016/j.ejca.2019.07.004_bib16) 2018; 36 Long (10.1016/j.ejca.2019.07.004_bib2) 2017; 377 |
References_xml | – volume: 36 year: 2018 ident: bib18 article-title: Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification publication-title: J Clin Oncol – volume: 50 start-page: 111 year: 2014 Jan end-page: 120 ident: bib9 article-title: The prognostic significance of sentinel node tumor burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients publication-title: Eur J Cancer – volume: 36 year: 2018 ident: bib16 article-title: External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III publication-title: J Clin Oncol – volume: 377 start-page: 1813 year: 2017 Nov 9 end-page: 1823 ident: bib2 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med – volume: 27 start-page: 6199 year: 2009 Dec 20 end-page: 6206 ident: bib4 article-title: Final version of 2009 AJCC melanoma staging and classification publication-title: J Clin Oncol – volume: 29 start-page: 2206 year: 2011 Jun 1 end-page: 2214 ident: bib8 article-title: Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria publication-title: J Clin Oncol – volume: 116 start-page: 148 year: 2019 Jul end-page: 157 ident: bib19 article-title: Prognostic and predictive value of AJCC-8 staging in the phase 3 EORTC 1325/Keynote-054 trial of pembrolizumab vs. placebeo in resected high-risk stage III melanoma publication-title: Eur J Cancer – volume: 17 start-page: 757 year: 2016 Jun end-page: 767 ident: bib12 article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol – volume: 116 start-page: 3178 year: 2010 Jul 1 end-page: 3188 ident: bib14 article-title: Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center publication-title: Cancer – volume: 67 start-page: 472 year: 2017 Nov end-page: 492 ident: bib5 article-title: Evidence based changes in the American Joint Committee on Cancer eighth edition cancer staging manual publication-title: CA Cancer J Clin – volume: 96 start-page: 25 year: 2018 Jun end-page: 33 ident: bib17 article-title: Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations publication-title: Eur J Cancer – volume: 115 start-page: 5026 year: 2009. Nov 1 end-page: 5037 ident: bib11 article-title: Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma publication-title: Cancer – volume: 29 start-page: 3588 year: 2011 end-page: 3590 ident: bib10 article-title: Parameters predicting prognosis in melanoma sentinel nodes publication-title: J Clin Oncol – volume: 91 start-page: 2110 year: 2001 end-page: 2121 ident: bib7 article-title: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma publication-title: Cancer – volume: 91 start-page: 168 year: 2018 Mar end-page: 170 ident: bib6 article-title: Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III publication-title: Eur J Cancer – volume: 377 start-page: 1824 year: 2017 Nov 9 end-page: 1835 ident: bib1 article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N Engl J Med – volume: 378 start-page: 1789 year: 2018 end-page: 1801 ident: bib3 article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma publication-title: N Engl J Med – volume: 24 start-page: 454 year: 2014 Oct end-page: 461 ident: bib13 article-title: Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? publication-title: Melanoma Res – volume: 11 start-page: 563 year: 2013 Jun end-page: 602 ident: bib15 article-title: S3-guideline “diagnosis, therapy and follow-up of melanoma” -- short version publication-title: J Dtsch Dermatol Ges – volume: 377 start-page: 1813 issue: 19 year: 2017 ident: 10.1016/j.ejca.2019.07.004_bib2 article-title: Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1708539 – volume: 91 start-page: 2110 year: 2001 ident: 10.1016/j.ejca.2019.07.004_bib7 article-title: A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma publication-title: Cancer doi: 10.1002/1097-0142(20010601)91:11<2110::AID-CNCR1239>3.0.CO;2-Q – volume: 50 start-page: 111 issue: 1 year: 2014 ident: 10.1016/j.ejca.2019.07.004_bib9 article-title: The prognostic significance of sentinel node tumor burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients publication-title: Eur J Cancer doi: 10.1016/j.ejca.2013.08.023 – volume: 116 start-page: 3178 issue: 13 year: 2010 ident: 10.1016/j.ejca.2019.07.004_bib14 article-title: Comparison of classification systems in melanoma sentinel lymph nodes--an analysis of 697 patients from a single center publication-title: Cancer doi: 10.1002/cncr.25074 – volume: 116 start-page: 148 year: 2019 ident: 10.1016/j.ejca.2019.07.004_bib19 article-title: Prognostic and predictive value of AJCC-8 staging in the phase 3 EORTC 1325/Keynote-054 trial of pembrolizumab vs. placebeo in resected high-risk stage III melanoma publication-title: Eur J Cancer doi: 10.1016/j.ejca.2019.05.020 – volume: 29 start-page: 2206 issue: 16 year: 2011 ident: 10.1016/j.ejca.2019.07.004_bib8 article-title: Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined rotterdam tumor load and dewar topography criteria publication-title: J Clin Oncol doi: 10.1200/JCO.2010.31.6760 – volume: 17 start-page: 757 issue: 6 year: 2016 ident: 10.1016/j.ejca.2019.07.004_bib12 article-title: Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)00141-8 – volume: 36 year: 2018 ident: 10.1016/j.ejca.2019.07.004_bib16 article-title: External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.9500 – volume: 29 start-page: 3588 issue: 26 year: 2011 ident: 10.1016/j.ejca.2019.07.004_bib10 article-title: Parameters predicting prognosis in melanoma sentinel nodes publication-title: J Clin Oncol doi: 10.1200/JCO.2011.37.1112 – volume: 11 start-page: 563 issue: 6 year: 2013 ident: 10.1016/j.ejca.2019.07.004_bib15 article-title: S3-guideline “diagnosis, therapy and follow-up of melanoma” -- short version publication-title: J Dtsch Dermatol Ges – volume: 24 start-page: 454 issue: 5 year: 2014 ident: 10.1016/j.ejca.2019.07.004_bib13 article-title: Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? publication-title: Melanoma Res doi: 10.1097/CMR.0000000000000081 – volume: 96 start-page: 25 year: 2018 ident: 10.1016/j.ejca.2019.07.004_bib17 article-title: Risk stratification of sentinel node-positive melanoma patients defines surgical management and adjuvant therapy treatment considerations publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.02.022 – volume: 115 start-page: 5026 issue: 21 year: 2009 ident: 10.1016/j.ejca.2019.07.004_bib11 article-title: Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma publication-title: Cancer doi: 10.1002/cncr.24298 – volume: 27 start-page: 6199 issue: 36 year: 2009 ident: 10.1016/j.ejca.2019.07.004_bib4 article-title: Final version of 2009 AJCC melanoma staging and classification publication-title: J Clin Oncol doi: 10.1200/JCO.2009.23.4799 – volume: 67 start-page: 472 issue: 6 year: 2017 ident: 10.1016/j.ejca.2019.07.004_bib5 article-title: Evidence based changes in the American Joint Committee on Cancer eighth edition cancer staging manual publication-title: CA Cancer J Clin doi: 10.3322/caac.21409 – volume: 36 year: 2018 ident: 10.1016/j.ejca.2019.07.004_bib18 article-title: Dabrafenib plus trametinib (D + T) as adjuvant treatment of resected BRAF-mutant stage III melanoma: findings from the COMBI-AD trial analyzed based on AJCC 8 classification publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.9591 – volume: 377 start-page: 1824 issue: 19 year: 2017 ident: 10.1016/j.ejca.2019.07.004_bib1 article-title: Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1709030 – volume: 91 start-page: 168 year: 2018 ident: 10.1016/j.ejca.2019.07.004_bib6 article-title: Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III publication-title: Eur J Cancer doi: 10.1016/j.ejca.2017.11.023 – volume: 378 start-page: 1789 year: 2018 ident: 10.1016/j.ejca.2019.07.004_bib3 article-title: Adjuvant pembrolizumab versus placebo in resected stage III melanoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1802357 |
SSID | ssj0007840 |
Score | 2.397231 |
Snippet | The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma... 1Background The tumor burden within the sentinel lymph node (SLN) is not included in the 8th edition of the American Joint Committee of Cancer (AJCC) melanoma... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 83 |
SubjectTerms | Benchmarks Biopsy Cancer Continuity (mathematics) Independent variables Lymph nodes Medical prognosis Melanoma Multivariate analysis Parameters Prognosis Sentinel lymph node Subgroups Survival Tumor burden Tumors |
Title | Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0959804919304046 https://dx.doi.org/10.1016/j.ejca.2019.07.004 https://www.ncbi.nlm.nih.gov/pubmed/31677550 https://www.proquest.com/docview/2330968475 https://www.proquest.com/docview/2311658827 |
Volume | 123 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED-VVkJ7QWPAKAPkSXtDoQ2JnWRvCIG6TeVhUIk3y3ZsqahNEG2ReOFv313iBCGxTtpjEl-U3J3vfrbvA-AbVyajDfwgzrMkiLWJAi0iFwwzzavWe6IqKTS-FqNJ_POO33XgosmFobBKb_trm15Za39n4Lk5eJhOBze0g5UiwEUIgpoYiw3onaG3T7vQO__xa3TdGuQkrfIi6x0vJPC5M3WYl703VH4ozKoanr5f2zv-6W_4s_JDVx9hywNIdl5_4zZ0bPEJNsf-iHwH5mM7U0U5VwElUVIgEFus0B6gRrFpwXwd1QWjDVhWh2w9WUYpSEg-Y7NnFC8rytwuvrPflHxOasFK9zpkuZqXj0xX-Q-7MLm6vL0YBb6nQmAQGC2D3OGKL0p0JtA1hVYPUTxK8NBYx3OVi9wabXSCMMAZND0udWFqOE9dpo1AMBjtQbcoC7sP7ExFCuUqlB3aOIuVQjTAE5Pj61XKnetD2HBSGl9wnPpezGQTWXYvifuSuC-HdA4e9-GkpXmoy22sHR01ApJNIimaPoneYC0Vb6neqNo_6Q4bHZB-oi8kcgQXgejieR--to9xitK5iypsuaIxVOMIlzJJHz7XutP-HBUiSHCVePCfH_UFPtBVHWBzCN3l48oeIUxa6mPYOH0Jj_1k-ANl0hE0 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swED9BkQYviI2vDtg8aW9T1IbETsJbhUBl0D5sIPFm2Y4tFbUJ6sek_fe7S5wgpAESr7EvSs7nu5_P9wHwnSuTkQM_iPMsCWJtokCLyAX9TPOq9Z6oSgqNxmJ4F_-85_drcN7kwlBYpdf9tU6vtLV_0vPc7D1OJr3f5MFKEeAiBEFJjMU6bMTU1LoDG4Or6-G4VchJWuVF1h4vJPC5M3WYl30wVH4ozKoanr5f23_s00v4s7JDlzuw7QEkG9Tf-BHWbPEJPoz8FfkuzEZ2qopypgJKoqRAILZYoT5AiWKTgvk6qgtGDlhWh2z9sYxSkJB8yqZ_cXlZUeZ2ccZ-UfI5iQUr3dOU5WpWzpmu8h_24O7y4vZ8GPieCoFBYLQMcocnvijRmUDTFFrdx-VRgofGOp6rXOTWaKMThAHOoOpxqQtTw3nqMm0EgsFoHzpFWdhDYKcqUriuQtm-jbNYKUQDPDE5vl6l3LkuhA0npfEFx6nvxVQ2kWUPkrgvifuyT_fgcRd-tDSPdbmNV2dHzQLJJpEUVZ9Ea_AqFW-pnonam3THjQxIv9EXEjmCh0A08bwL39ph3KJ076IKW65oDtU4wqNM0oWDWnban6NCBAmeEj-_86O-wubwdnQjb67G10ewRSN1sM0xdJbzlT1ByLTUX_yW-AfTOBMa |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Melanoma-specific+survival+in+patients+with+positive+sentinel+lymph+nodes%3A+Relevance+of+sentinel+tumor+burden&rft.jtitle=European+journal+of+cancer+%281990%29&rft.au=Satzger%2C+Imke&rft.au=Leiter%2C+Ulrike&rft.au=Gr%C3%A4ger%2C+Nikolai&rft.au=Keim%2C+Ulrike&rft.date=2019-12-01&rft.pub=Elsevier+Science+Ltd&rft.issn=0959-8049&rft.eissn=1879-0852&rft.volume=123&rft.spage=83&rft_id=info:doi/10.1016%2Fj.ejca.2019.07.004&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0959-8049&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0959-8049&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0959-8049&client=summon |